The impacts of trauma and stress on orexin expression and signalling: A systematic review.

Psychiatry ResMay 11, 2026 (epub)
Clinical ResearchPsychiatry

Kelei Xiao, Hisham Sayed, Jason Xing et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the effects of trauma and stress on orexin expression and signaling across preclinical and clinical studies. It found that acute stress leads to a 1.55-fold increase in orexin neuronal activation, while chronic stress and PTSD are linked to increased orexin receptor responsivity. Additionally, childhood trauma correlates with decreased orexin receptor 1 expression and increased plasma orexin-B levels in Major Depressive Disorder.

Key findings

  • Acute stress is associated with a 1.55-fold increase in orexin neuronal activation (p< 0.05).
  • Chronic stress and PTSD correlate with increased orexin receptor responsivity (t = 3.51, p= 0.011).
  • Childhood trauma is linked to a 2-fold decrease in orexin receptor 1 expression in the amygdala (p<0.05).
  • Childhood trauma is associated with increased plasma orexin-B concentration in Major Depressive Disorder (p < 0.001).

Why it matters

Understanding the relationship between trauma, stress, and orexin signaling can inform treatment strategies for stress-related disorders, including PTSD and depression. This knowledge may lead to targeted interventions that address orexin pathways.

Source

Published in Psychiatry Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.